Status:
COMPLETED
Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer
Lead Sponsor:
Jun Zhang
Conditions:
Advanced Ovarian Cancer
Eligibility:
FEMALE
20-70 years
Phase:
NA
Brief Summary
Tranexamic acid has been used in surgery for more than 30 years. It's effect on reducing bleeding and blood transfusing has been demonstrated. In our hospital, the amount of cytorsductive surgery for...
Detailed Description
We performed a single blind, prospective, randomised control trial (RCT) . The patients randomised assigned to three groups. Low dose TXA, high dose TXA or a placebo of IV saline which will be infused...
Eligibility Criteria
Inclusion
- sign the informed consent
- Aged 20-70 years
- ovarian cancer patients, staged IIIB - C or above
- 3\) ASA I - II
Exclusion
- tranexamic acid allergy
- pregnancy and lactation
- only lymph node metastasise
- history of mental disorder, immune system disorder
- history of epilepsy, dyschromatopsia
- arrhythmia
- history of renal insufficiency
- thrombosis related disease
- Hb \< 90 g/dL
- using anticoagulant drugs (not including aspirin discontinuation 1 week
- having participated in other clinical trials, or refusing to join the research.
Key Trial Info
Start Date :
June 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2021
Estimated Enrollment :
151 Patients enrolled
Trial Details
Trial ID
NCT04360629
Start Date
June 3 2020
End Date
December 30 2021
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Cancer Center, Fudan University
Shanghai, Shanghai Municipality, China, 200040